Skip to main content

Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy

Abstract

Fulvestrant (Faslodex®), a selective estrogen receptor (ER) degrader, is now indicated for the treatment of ER+ or hormone-receptor positive (HR+)/HER2− advanced breast cancer in postmenopausal women previously untreated with endocrine therapy. In the phase 3 FALCON trial conducted in this setting, intramuscular fulvestrant 500 mg/month (plus an additional dose at 2 weeks) was significantly more effective in prolonging progression-free survival (PFS) than oral anastrozole 1 mg/day (particularly in patients with non-visceral disease), with this benefit seemingly driven by fulvestrant recipients responding significantly longer to treatment. Other efficacy measures, including objective response rate, did not significantly or markedly differ between the two regimens and median overall survival was not yet calculable. Fulvestrant was generally well tolerated in this trial, displaying an overall tolerability profile consistent with its known tolerability in other breast cancer settings. Thus, monotherapy with intramuscular fulvestrant is a generally well tolerated and more effective treatment option than standard-of-care anastrozole for ER+ or HR+/HER2− advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.

This is a preview of subscription content, access via your institution.

References

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  2. Kumler I, Knoop AS, Jessing CAR, et al. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open. 2016;1(4):e000062.

    Article  PubMed  PubMed Central  Google Scholar 

  3. American Cancer Society. Breast cancer facts and figures 2015–2016. 2015. https://www.cancer.org. Accessed 17 Nov 2017.

  4. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28(1):16–33.

    CAS  PubMed  Google Scholar 

  5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Breast cancer version 3.2017. 2017. http://www.nccn.org. Accessed 11 Dec 2017.

  6. AstraZeneca UK Limited. Faslodex 250 mg solution for injection: EU summary of product characteristics. 2017. http://www.ema.europa.eu/ema. Accessed 11 Dec 2017.

  7. AstraZeneca. Faslodex® (fulvestrant) injection, for intramuscular use: US prescribing information. 2017. https://www.accessdata.fda.gov. Accessed 11 Dec 2017.

  8. Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs. 2011;71(3):363–80.

    CAS  Article  PubMed  Google Scholar 

  9. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–73.

    CAS  PubMed  Google Scholar 

  10. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61(18):6739–46.

    CAS  PubMed  Google Scholar 

  11. Kuter I, Gee JM, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133(1):237–46.

    CAS  Article  PubMed  Google Scholar 

  12. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. de Cupis A, Noonan D, Pirani P, et al. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br J Pharmacol. 1995;116(5):2391–400.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994;54(6):1587–95.

    CAS  PubMed  Google Scholar 

  15. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer. 1994;70(2):204–11.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Coradini D, Biffi A, Cappelletti V, et al. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells. Anticancer Res. 1994;14(3A):1059–64.

    CAS  PubMed  Google Scholar 

  17. Hu XF, Veroni M, De Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer. 1993;55(5):873–6.

    CAS  Article  PubMed  Google Scholar 

  18. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995;87(10):746–50.

    CAS  Article  PubMed  Google Scholar 

  19. Bundred NJ, Anderson E, Nicholson RI, et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res. 2002;22(4):2317–9.

    CAS  PubMed  Google Scholar 

  20. DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994;54(2):408–14.

    CAS  PubMed  Google Scholar 

  21. Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer. 1996;74(2):300–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Frassoldati A, Guarneri V, Conte P. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. Cancer Biol Ther. 2009;8(15):1456–8.

    CAS  Article  PubMed  Google Scholar 

  23. Belagali YR, Barkate HV, Sejpal JJ, et al. Therapeutic place of fulvestrant in the management of hormone-receptor positive breast cancer. Eur Oncol Haematol. 2016;12(1):44–50.

    Article  Google Scholar 

  24. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.

    CAS  Article  PubMed  Google Scholar 

  25. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5.

    CAS  Article  PubMed  Google Scholar 

  26. Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136(2):503–11.

    CAS  Article  PubMed  Google Scholar 

  27. Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33(32):3781–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Robertson JFR, Cheung K-L, Noguchi S, et al. Health-related quality of life from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON) [abstract no. 1048]. J Clin Oncol. 2017;35(15 Suppl.).

  29. Roberston JFR, Di Leo A, Fazal M, et al. Fulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral vs non-visceral metastases: findings from FALCON, FIRST, and CONFIRM [abstract]. In: San Antonio Breast Cancer Symposium, 2017.

  30. Nunes AP, Green E, Dalvi T, et al. A real-world evidence study to define the prevalence of endocrine therapy-naive hormone receptor-positive locally advanced or metastatic breast cancer in the US [abstract no. P5-08-20]. Cancer Res. 2017;77(4 Suppl.).

  31. Bastiaannet E, Charman J, Borge Johannesen T, et al. A real-world evidence study of patients with hormone receptor positive locally advanced or metastatic breast cancer at primary diagnosis [abstract no. 377]. Eur J Cancer. 2016;57(Suppl. 2):S107–8.

    Google Scholar 

  32. Boer K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017;9(7):465–79.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ding H, Fang L, Xin W, et al. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. Eur J Cancer Care (Engl). 2017. https://doi.org/10.1111/ecc.12733.

  34. Robert NJ, Denduluri N. Patient case lessons: endocrine management of advanced breast cancer. Clin Breast Cancer. 2017. https://doi.org/10.1016/j.clbc.2017.05.014.

  35. Telford C, Takyar S, Joshi P, et al. A network meta-analysis of fulvestrant vs alternative first-line endocrine therapies for endocrine therapy-naive postmenopausal hormone receptor-positive advanced or metastatic breast cancer [abstract no. e12545]. J Clin Oncol. 2017;35(15 Suppl).

  36. Zhang J, Huang Y, Wang C, et al. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: a network meta-analysis. Medicine (Baltimore). 2017;96(33):e7846.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017;59:22–32.

    CAS  Article  PubMed  Google Scholar 

  38. Baatjes KJ, Apffelstaedt JP, Kotze MJ, et al. Postmenopausal breast cancer, aromatase inhibitors, and bone health: what the surgeon should know. World J Surg. 2016;40(9):2149–56.

    CAS  Article  PubMed  Google Scholar 

  39. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.

    CAS  Article  PubMed  Google Scholar 

  40. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of fulvestrant was also offered the opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emma D. Deeks.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/C7CCF06013B1BD22.

Additional information

The manuscript was reviewed by: A. M. Brufsky, University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, PA, USA; S. Gonnelli, Department of Internal Medicine, University of Siena, Siena, Italy.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy. Drugs 78, 131–137 (2018). https://doi.org/10.1007/s40265-017-0855-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0855-5